Pregled bibliografske jedinice broj: 1192843
Pharmacogenetic distinction of the Croatian population from the European average
Pharmacogenetic distinction of the Croatian population from the European average // Croatian medical journal, 63 (2022), 2; 117-125 doi:10.3325/cmj.2022.63.117 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1192843 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Pharmacogenetic distinction of the Croatian
population from the European average
(Pharmacogenetic distinction of the Croatian
population from the European average.)
Autori
Celinšćak, Željka ; Zajc Petranović, Matea ; Šetinc, Maja ; Stojanović Marković, Anita ; Peričić Salihović, Marijana ; Zeljko, Hrvojka Marija ; Janićijević, Branka ; Smolej Narančić, Nina ; Škarić-Jurić, Tatjana
Izvornik
Croatian medical journal (0353-9504) 63
(2022), 2;
117-125
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
ADME ; Croatian population ; gnomAD ; population genetics ; pharmacotherapy ; drug–gene interaction ; anticoagulants ; warfarin
Sažetak
Aim: To compare the Croatian and European population in terms of allele frequencies of clinically relevant polymorphisms in drug absorption, distribution, metabolism, and excretion (ADME) genes. Methods: In 429 Croatian participants, we genotyped 27 loci in 20 ADME genes. The obtained frequencies were merged with the published frequencies for the Croatian population by sample size weighting. The study sample obtained in this way was compared with the average data for the European population from the gnomAD database. Results: Variant allele frequencies in the Croatian population were higher in three and lower in two polymorphisms (Benjamini-Hochberg-corrected P values: 0.0027 for CYP2B6*4 rs2279343, CYP2C9*2 rs1799853, and VKORC1 rs9923231 ; 0.0297 for GSTP1 rs1695 ; 0.0455 for CYP2A6 rs1801272) compared with the European population. The most marked difference was observed for CYP2B6*4 (9.3% in Europe vs 24.3% in Croatia). The most clinically relevant findings were higher variant allele frequencies in two polymorphisms related to lower warfarin requirements: VKORC1*2 (34.9% in Europe vs 40.1% in Croatia) and CYP2C9*2 (12.3% in Europe vs 14.7% in Croatia). This indicates that three- quarters of Croatian people have at least one variant allele at these loci. Variants in genes GSTP1 and CYP2A6 were significantly less frequently observed in Croatia. Conclusions: Croatian population has a higher bleeding and over-anticoagulation risk, which is why we recommend the prescription of lower doses of anticoagulation drugs such as warfarin and acenocoumarol. Lower phenytoin, and higher bupropion and efavirenz doses are also recommended in the Croatian population.
Izvorni jezik
Engleski
Znanstvena područja
Biologija, Javno zdravstvo i zdravstvena zaštita, Farmacija, Etnologija i antropologija
POVEZANOST RADA
Projekti:
IP-2018-01-2497 - Zdravstvene, kulturne i biološke odrednice dugovječnosti: antropološka studija preživljenja u dubokoj starosti (HECUBA) (Škarić-Jurić, Tatjana, HRZZ - 2018-01) ( CroRIS)
IP-2014-09-4454 - utjecaj podrijetla i izolacije na ADME gene: primjer romske populacije (ADMEROMA) (Peričić Salihović, Marijana, HRZZ - 2014-09) ( CroRIS)
Ustanove:
Institut za antropologiju,
Medicinski fakultet, Osijek
Profili:
Hrvojka Marija Zeljko
(autor)
Matea Zajc Petranović
(autor)
Anita Stojanović
(autor)
Željka Celinšćak
(autor)
Marijana Peričić Salihović
(autor)
Tatjana Škarić-Jurić
(autor)
Branka Janićijević
(autor)
Maja Šetinc
(autor)
Nina Smolej-Narančić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE